The impact of cost sharing on antidepressant use among older adults in British Columbia

Psychiatric Services

Volumn 59, Issue 4, 2008, Pages 377-383

  Wang, Philip S ^a   Patrick, Amanda R ^b   Dormuth, Colin R ^c   Avorn, Jerry ^b   Maclure, Malcolm ^d   Canning, Claire F ^b   Schneeweiss, Sebastian ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF VICTORIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; IMIPRAMINE; SEROTONIN UPTAKE INHIBITOR; ADRENERGIC RECEPTOR AFFECTING AGENT; ANTIDEPRESSANT AGENT;

AGED; ARTICLE; CANADA; DEPRESSION; DRUG COST; DRUG USE; FEMALE; HEALTH CARE POLICY; HUMAN; INSURANCE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRESCRIPTION; COST; DRUG THERAPY; MIDDLE AGED; PREVALENCE; STATISTICS; UTILIZATION REVIEW;

ADRENERGIC UPTAKE INHIBITORS; AGED; ANTIDEPRESSIVE AGENTS; BRITISH COLUMBIA; COST SHARING; DEPRESSIVE DISORDER; DRUG THERAPY; FEMALE; HEALTH POLICY; HUMANS; IMIPRAMINE; MALE; MIDDLE AGED; PREVALENCE;

EID: 85047681310     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/ps.2008.59.4.377     Document Type: Article

References (61)

1. Lebowitz BD, Pearson JL, Schneider LS, et al: Diagnosis and treatment of depression in late life: consensus statement update. JAMA 278:1186-1190, 1997
2. Brnce MP, Leaf P, Rozal G, et al: Psychiatry status and 9-year mortality data in the New Haven Epidemiologic Catchment Area Study. American Journal of Psychiatry 51: 716-721, 1994
3. Uniitzer J, Patrick DL, Simon G, et al: Depressive symptoms and cost of health Services in HMO patients aged 65 years and older. JAMA 277:1618-1623, 1997
4. Blazer DG: The OARS Durham surveys: description and application, in Multidimensional Functional Assessment: The OARS Methodology: A Manual, 2nd ed. Durham, NC, Center for the Study of Aging and Human Development, 1978
5. Olfson M, Pincus HA: Outpatient and mental health care in nonhospital settings: distribution of patients across provider groups. American Journal of Psychiatry 153:1353-1356, 1996
6. Wang PS, Schneeweiss S, Brookhart MA, et al: Suboptimal antidepressant use in the elderly. Journal of Clinical Psychopharmacology 25:118-126, 2005
7. Avorn J, Wang PS: Prescribing psychotropic drugs for the elderly: epidemiologic and policy considerations, in Clinical Geriatric Psychopharmacology, 4th ed. Edited by Salzman C. New York, McGraw-Hill, 2004
8. Schneider LS: Pharmacologic considerations in the treatment of late-life depression. American Journal of Geriatric Psychiatry 4 (suppl):S51-S65, 1996
9. Caine E, Lyness JM, Conwell Y: Diagnosis of late-life depression: preliminary studies in primary care settings. American Journal of Geriatric Psychiatry 4:45-51, 1996
10. Gurland B, Cross P, Katz S: Epidemiologic perspectives on opportunities for treatment of depression. American Journal of Geriatric Psychiatry 4:7-14, 1996
11. Luber MP, Meyers BS, Williams-Russo PG, et al: Depression and Service utilization in elderly primary care patients. American Journal of Geriatric Psychiatry 9:169-176, 2001
12. Blanchard MR, Waterreus A, Mann AH: The nature of depression among older people in inner London and the contact with primary care. British Journal of Psychiatry 164:396-402, 1994
13. Unützer J, Simon G, Belin TR, et al: Care for depression in HMO patients aged 65 and older. Journal of the American Geriatrics Society 48:871-878, 2000
14. Medicare Prescription Drug Benefit Fact Sheet. Menlo Park, Calif, Henry J Kaiser Family Foundation, 2007. Available at www.kff.org/medicare/urpload/ 704407.pdf
15. Mark TL, Coffey RM, McKusick DR, et al: National Estimates of Expenditures for Mental Health Services and Substance Abuse Treatment, 1991-2001. SAMHSA pub no SMA 05-3999. Rockville, Md, Substance Abuse and Mental Health Services Administration, 2005
16. Pincus HA, Tanielian TL, Marcus SC, et al: Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties. JAMA 279:526-531, 1998
17. Evidence Report on Treatment of Depression - Newer Pharmacotherapies. AHCPR pub no 99-E0130. Washington, DC, Agency for Health Care Policy and Research, 1999
18. Lydiard RR, Rrawman-Mintzer O, Ballenger JC: Recent developments in the psychopharmacology of anxiety disorders. Journal of Consulting and Clinical Psychology 64:660-668, 1996
19. Mamdani MM, Parikh SV, Austin PC, et al: Use of antidepressants among elderly subjects: trends and contributing factors. JAMA 157:360-367, 2000
20. Harvard Pilgrim (HMO) prescription drug costs. Boston Globe, March 18, 1998
21. Hoadley J, Hargrave E, Cubanski J, et al: An In-Depth Examination of Formularies and Other Features of Medicare Drug Plans. Menlo Park, Calif, Kaiser Family Foundation, Apr 2006. Available at www.kff.org/medicare/upload/7489.pdf
22. Tamblyn R, Laprise R, Hanley JA, et al: Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 285:421-429, 2001
23. Hsu J, Price M, Huang J, et al: Unintended consequences of caps on Medicare drug benefits. New England Journal of Medicine 354:2349-2359, 2006
24. Roblin DW, Platt R, Goodman MJ, et al: Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations: how much is too much? Medical Care 43:951-959, 2005
25. Anderson GM, Kerluke KJ, Pulcins IR, et al: Trends and determinants of prescriptions drug expenditures in the elderly: data from the British Columbia Pharmacare Program. Inquiry 30:199-207, 1993
26. Wilchesky M, Tamblyn RM, Huang A: Validation of diagnostic codes within medical Services claims. Journal of Clinical Epidemiology 57:131-141, 2004
27. Folwes JB, Lawthers AG, Weiner JP, et al: Agreement between physicians' office records and Medicare Part B claims data. Health Care Financing Review 16:189-199, 1995
28. Salzman C: Clinical Geriatric Psychopharmacology, 4th ed. Philadelphia, Lippincott Williams and Wilkins, 2005
29. Health Data Warehouse. Victoria, British Columbia, BC Ministry of Health Services. Available at admin.moh.hnet.bc.ca/hdw. Accessed Sept 17, 2004
30. Wagner AK, Soumerai SB, Zhang F, et al: Segmented regression analysis of interrupted time series studies in medication use research. Journal of Clinical Pharmacy and Therapeutics 27:299-309, 2002
31. Huskamp HA, Deverka PA, Epstein AM, et al: The effect of incentive-based formularies on prescription drug-utilization and spending. New England Journal of Medicine 349:2224-2232, 2003
32. Roemer MI, Hopkins CE, Carr L, et al: Co-payments for ambulatory care: penny-wise and pound foolish. Medical Care 13:457-466, 1975
33. Soumerai SB, Avorn J, Ross-Degnan D, et al: Payment restrictions for prescription drugs in Medicaid: effects on therapy, cost, and equity. New England Journal of Medicine 317:550-556, 1987
34. Reeder CE, Nelson AA: The differential impact of copayment on drug use in a Medicaid population. Inquiry 22:396-403, 1985
35. Nelson AA, Reeder CE, Dickson WM: The effect of a Medicaid drug copayment program on the utilization and cost of prescription Services. Medical Care 22:724-736, 1984
36. Harris BL, Stergachis A, Ried LD: The effect of drug co-payments on utilization and cost of pharmaceuticals in a HMO. Medical Care 28:907-917, 1990
37. Leibowitz A, Manning WG, Newhouse JP: The demand for prescription drugs as a function of cost-sharing. Social Science and Medicine 21:1063-1069, 1985
38. Lohr KN, Brook RH, Kamberg CJ et al: Use of medical care in the RAND Health Insurance Experiment: diagnosis- and Service-specific analyses in a randomized controlled trial. Medical Care 24(suppl):S39-S50, 1986
39. Johnson RE, Goodman MJ, Hornbrook MC, et al: The impact of increasing patient prescription drug cost sharing on therapeutic classes of drugs received and on the health status of elderly HMO members. Health Service Research 31:103-122, 1997
40. Goldman DP, Joyce GF, Escarce JJ, et al: Pharmacy benefits and the use of drugs by the chronically ill. JAMA 291:2344-2350, 2004
41. Safran DG, Neuman P, Schoen C, et al: Prescription drug coverage and seniors: findings from a 2003 national survey. Health Affairs 19:W5-152-W5-166, 2005
42. Iglehart JK: Health Policy 2001: Medicare and prescription drugs. New England Journal of Medicine 344:1010-1015, 2001
43. Unützer J, Katon W, Russo J, et al: Patterns of care for depressed older adults in a large staff-model HMO. American Journal of Geriatric Psychiatry 7:235-243, 1999
44. Callahan CM: Quality improvement research on late life depression in primary care. Medical Care 39:772-784, 2001
45. NIH Consensus Development Panel on Depression in Late Life: Diagnosis and treatment of depression in late life. JAMA 268: 1018-1024, 1992
46. Cole MG, Yaffe MJ: Pathway to psychiatric care of the elderly with depression. International Journal of Geriatric Psychiatry 11:157-161, 1996
47. Swartz MS, Wagner HR, Swanson JW, et al: Administrative update: utilization of Services: I. comparing use of public and private mental health Services: the enduring barriers of race and age. Community Mental Health Journal 34:133-144, 1998
48. Soumerai SB, Ross-Degnan D, Avorn J, et al: Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. New England Journal of Medicine 325: 1072-1077, 1991
49. Johnson RE, Goodman MJ, Hornbrook MC, et al: The effect of increased prescription drug cost-sharing on medical care utilization and expenses of elderly health maintenance organization members. Medical Care 35: 1119-1131, 1997
50. Thomas M, Mann J, Williams S: The impact of reference pricing on clinical lipid control. New Zealand Medical Journal 111:292-294, 1998
51. Thomas M, Mann J: Increased thrombotic vascular events after change of statin. Lancet 352:1830-1831, 1998
52. Motheral B, Fairman KA: Effect of a threetier prescription copay on pharmaceutical and other medical utilization. Medical Care 39:1293-1304, 2001
53. Grootendorst PV, Dolovich LR, O'Brien BJ, et al: Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs. Canadian Medical Association Journal 165:1011-1019, 2001
54. Marshall JK, Grootendorst PV, O'Brien BJ, et al: Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia. Canadian Medical Association Journal 166:1655-1662, 2002
55. Hazlet TK, Blough DK: Health Services utilization with reference drug pricing of histamine(2) receptor antagonists in British Co-lumbia elderly. Medical Care 40:640-649, 2002
56. Schneeweiss S, Walker AM, Glynn RJ, et al: Outcomes of reference pricing for angiotensin-converting enzyme inhibitors. New England Journal of Medicine 346:822-829, 2002
57. Schneeweiss S, Soumerai SB, Glynn RJ, et al: Impacts of reference pricing for ACE inhibitors on drug utilization. Canadian Medical Association Journal 166:737-748, 2002
58. Schneeweiss S, Soumerai SB, Maclure M, et al: Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clinical Pharmacology and Therapeutics 74:388-400, 2003
59. Schneeweiss S, Dormuth C, Grootendorst P, et al: Net health plan savings from reference drug pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents. Medical Care 42:653-660, 2004
60. Soumerai SB, McLaughlin TJ, Ross-Degnan D, et al: Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health Services by patients with schizophrenia. New England Journal of Medicine 331:650-655, 1994
61. Unützer J, Katon W, Callahan C, et al: Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA 288:2836-2845, 2002